First Dallas Securities Inc. cut its position in shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 40.5% during the second quarter, Holdings Channel reports. The fund owned 11,250 shares of the specialty pharmaceutical company’s stock after selling 7,650 shares during the period. First Dallas Securities Inc.’s holdings in Supernus Pharmaceuticals were worth $229,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of Montreal Can bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth $199,000. Boothbay Fund Management LLC bought a new position in shares of Supernus Pharmaceuticals during the first quarter worth $203,000. BNP Paribas Arbitrage SA increased its position in shares of Supernus Pharmaceuticals by 126.3% in the second quarter. BNP Paribas Arbitrage SA now owns 11,478 shares of the specialty pharmaceutical company’s stock worth $234,000 after buying an additional 6,407 shares during the last quarter. Arizona State Retirement System increased its position in shares of Supernus Pharmaceuticals by 6.0% in the first quarter. Arizona State Retirement System now owns 17,601 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 1,000 shares during the last quarter. Finally, Springbok Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 88.0% in the first quarter. Springbok Capital Management LLC now owns 19,927 shares of the specialty pharmaceutical company’s stock worth $304,000 after buying an additional 9,327 shares during the last quarter. 94.66% of the stock is currently owned by institutional investors and hedge funds.
Shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) traded up 0.38% during mid-day trading on Wednesday, hitting $26.68. The stock had a trading volume of 561,712 shares. Supernus Pharmaceuticals Inc. has a 52 week low of $9.51 and a 52 week high of $26.84. The stock has a market capitalization of $1.32 billion, a P/E ratio of 54.45 and a beta of 1.77. The stock has a 50 day moving average of $23.22 and a 200-day moving average of $19.61.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The firm had revenue of $50.40 million for the quarter, compared to analyst estimates of $49.67 million. During the same quarter last year, the company earned $0.03 EPS. The company’s revenue was up 43.6% on a year-over-year basis. On average, equities research analysts predict that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current year.
SUPN has been the topic of several recent analyst reports. Jefferies Group reaffirmed a “buy” rating and issued a $28.00 price target (up from $23.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 4th. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 6th. Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective on the stock. in a report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Monday, July 18th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $24.50.
In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the firm’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares in the company, valued at approximately $90,400. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 6.10% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.